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a b s t r a c t
Effective oncolytic virus (OV) therapy is dependent on the ability of replication-competent viruses to kill
infected cancer cells. We previously showed that human pancreatic ductal adenocarcinoma (PDAC) cell
lines are highly heterogeneous in their permissiveness to vesicular stomatitis virus (VSV), in part due to
differences in type I interferon (IFN) signaling. Here, using 10 human PDAC cell lines and three different
VSV recombinants (expressing ΔM51 or wild type matrix protein), we examined cellular and viral factors
affecting VSV-mediated apoptosis activation in PDACs. In most cell lines, VSVs activated both extrinsic
and intrinsic apoptosis pathways, and VSV-ΔM51 primarily activated the type II extrinsic pathway. In
cells with defective IFN signaling, all VSV recombinants induced robust apoptosis, whereas VSV-ΔM51
was a more effective apoptosis activator in PDACs with virus-inducible IFN signaling. Three cell lines
constitutively expressing high levels of IFN-stimulated genes (ISGs) were resistant to apoptosis under
most experimental conditions, even when VSV replication levels were dramatically increased by Jak
inhibitor I treatment. Two of these cell lines also poorly activated apoptosis when treated with Fas
activating antibody, suggesting a general defect in apoptosis.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Oncolytic virus (OV) therapy is an innovative anticancer approach
utilizing replication-competent viruses that preferentially infect and
kill cancer cells [reviewed in Russell et al. (2012)]. Vesicular stoma-
titis virus (VSV), a prototypic non-segmented negative-strand RNA
virus (order Mononegavirales, family Rhabdoviridae), is a promising
oncolytic virus against various malignancies [reviewed in Barber
(2004) and Hastie and Grdzelishvili (2012)], and a phase I clinical
trial using VSV against hepatocellular carcinoma is in progress
(http://clinicaltrials.gov, trial NCT01628640). While wild type (wt)
VSV cannot be utilized as an OV due to its unacceptable neurotoxi-
city, numerous VSV-based recombinants with signiﬁcantly decreased
neurotoxicity and improved oncoselectivity have been generated
[reviewed in Hastie and Grdzelishvili (2012)]. One of the best
performing oncolytic VSVs is VSV with replacement or deletion of
the methionine at amino acid position 51 (M51) of the VSV matrix
(M) protein. The oncoselectivity (and safety) of VSV M51 mutants is
largely based on their inability to evade type I interferon (IFN)
mediated antiviral responses in non-malignant cells (Ahmed et al.,
2003; Brown et al., 2009; Ebert et al., 2005; Stojdl et al., 2003;
Trottier et al., 2007; Wollmann et al., 2010). However, cancer cells
often have defects in type I IFN signaling, which can provide a growth
advantage to uninfected cells, but impairs their ability to inhibit VSV
infection and replication [reviewed in Barber (2005), Hastie et al.
(2013) and Lichty et al. (2004)].
Pancreatic cancer is one of the most lethal abdominal malig-
nancies with annual deaths closely matching the annual incidence
of the disease [reviewed in Farrow et al. (2008)]. About 95% of
pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC),
which are highly invasive with aggressive local growth and rapid
metastases to surrounding tissues [reviewed in Stathis and Moore
(2010)]. Our recent studies demonstrated that VSV is very effective
against the majority of human PDAC cell lines, both in vitro and
in vivo, but that some cell lines are resistant to VSV replication and
oncolysis (Moerdyk-Schauwecker et al., 2013; Murphy et al., 2012).
All cell lines resistant to VSV retained functional type I IFN
responses (Moerdyk-Schauwecker et al., 2013; Murphy et al.,
2012) and displayed constitutive high-level expression of the
IFN-stimulated antiviral genes MxA and OAS (Moerdyk-
Schauwecker et al., 2013; Murphy et al., 2012). Inhibition of JAK/
STAT signaling by Jak inhibitor I (Jak Inh. I) decreased levels of MxA
and OAS and increased VSV replication (Moerdyk-Schauwecker et
al., 2013).
Effective oncolytic virus (OV) therapy depends not only on the
ability of OVs to infect and replicate in cancer cells, but also to kill
them. VSV kills infected cells primarily via induction of apoptosis
(Balachandran et al., 2001; Balachandran et al., 2000; Cary et al.,
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2011; Gadaleta et al., 2005; Gaddy and Lyles 2005; Gaddy and
Lyles 2007; Kopecky and Lyles, 2003; Kopecky et al., 2001). The
speciﬁc mechanism of apoptosis in response to VSV infection
depends on both virus and cell type, and apoptosis induction has
never been studied in any pancreatic cancer cells in response to
VSV. Thus, the goals of this study were (1) to investigate the
mechanism of apoptosis induction in PDAC cell lines by three
different viruses: wt-like VSV (VSV-GFP) and VSV attenuated by M
dependent and independent mechanisms (VSV-ΔM51-GFP and
VSV-P1-GFP respectively; and (2) to examine whether dysregula-
tion of apoptosis, a hallmark of PDACs as well as other cancers
[reviewed in Hamacher et al. (2008), Neesse et al. (2012) and
Roder et al. (2011)], contributes to the resistance of some PDACs to
VSV-mediated oncolysis. For example, in chronic lymphocytic
leukemia (CLL) cells overexpressing the anti-apoptotic protein
Bcl-2, VSV-M51R (M51R substitution in M protein) was unable to
induce apoptosis and consequently the CLL cells were resistant to
VSV-induced killing (Tumilasci et al., 2008).
The use of a VSV recombinant with the M51 deletion in the M
protein (unable to evade type I IFN responses), and two VSV
recombinants with wt M protein revealed possible links between
apoptosis and type I IFN signaling in PDAC cell lines. Moreover, the
ability of PDAC cells to undergo apoptosis following non-viral stimuli
was also examined. Finally, as apoptosis activation may reduce viral
replication (and potentially reduce oncolytic virus efﬁciency), as has
been reported for many viruses [reviewed in Galluzzi et al. (2008) and
O’Brien (1998)] including, in some instances, VSV (Chattopadhyay et
al., 2011; Desforges et al., 2002; Sharif-Askari et al., 2007), the effect of
apoptosis activation on VSV replication in PDAC cells was examined.
Revealing mechanisms of VSV-mediated apoptosis in PDAC cells is
important for understanding virus–host interactions in cancer cells. In
addition, understanding mechanisms of resistance of cancer cells to
VSV and other OVs is critical for developing effective OV approaches,
identifying biomarkers and developing approaches to break resistance.
Results
Human PDAC cells are highly heterogeneous in their abilities to
activate apoptosis following VSV infection
Effective OV therapy is dependent on the ability of a replication-
competent virus to kill infected cancer cells. Although VSV mediated
apoptosis was studied in other systems (Balachandran et al., 2001,
2000; Cary et al., 2011; Gadaleta et al., 2005; Gaddy and Lyles 2005,
2007; Sharif-Askari et al., 2007), the mechanism of apoptosis induc-
tion by VSV in pancreatic cancer cells has never been examined.
Our major focus is the commonly used VSV recombinant with
the ΔM51 mutation in the M gene (Brown et al., 2009; Ebert et al.,
2005; Stojdl et al., 2003; Wollmann et al., 2010). The recombinant
VSV-ΔM51-GFP used in this study also contains the GFP ORF at
position 5 of the viral genome (between G and L) (Fig. 1), which
only marginally affects VSV replication, but allows for monitoring
of VSV infection, replication, and spread, based on virus-driven
GFP expression (Wollmann et al., 2010). Several experiments also
utilized two VSV recombinants encoding the wt M gene: VSV-GFP
and VSV-p1-GFP (Fig. 1). VSV-GFP has the same GFP insertion as
VSV-ΔM51-GFP but wt M gene, allowing study of the role of M
protein in apoptosis induction. VSV-p1-GFP, also has the wt M
gene, but insertion of the GFP ORF at position 1 of the VSV genome
results in slower viral replication kinetics (Ramsburg et al., 2005;
Wollmann et al., 2010), allowing for examination of the role of M
protein independent virus attenuation in apoptosis induction
(Ramsburg et al., 2005; Wollmann et al., 2010).
To examine the ability of VSV recombinants to induce apoptosis
in PDAC cells, a panel of 10 clinically relevant human PDAC cell
lines was used (Table 1). These cells have been characterized in our
previous studies for their permissiveness to VSV as well as their
type I IFN signaling status (Moerdyk-Schauwecker et al., 2013;
Murphy et al., 2012) (summarized in Table 1). Importantly, two of
these PDAC cell lines (MIA PaCa-2 and Capan-1, indicated in all
ﬁgures using green font) are highly permissive to VSV and
defective in antiviral signaling in response to VSV infection; four
cell lines (Capan-2, AsPC-1, Suit2, and T3M4, black font) are
permissive to VSV but have VSV-inducible IFN signaling; two cell
lines (CFPAC-1 and HPAC, blue font) are moderately permissive to
VSV (resistant only at low MOIs) and have VSV-inducible IFN
signaling and constitutive expression of MxA and OAS; and two
cell lines (HPAF-II and Hs766T, red font) are highly resistant to VSV
(at all tested MOIs) and have VSV-inducible IFN signaling and
constitutive expression of MxA and OAS.
Cells were mock-treated or infected at an MOI of 15 (based on
virus titration on BHK-21 cells) with VSV-ΔM51-GFP, VSV-p1-GFP
or VSV-GFP. Protein was isolated at 17 hours (h) post infection (p.i.)
and Western blotting performed to examine VSV replication, ISG
expression and the presence or absence of cleaved caspases and
other apoptosis related factors. Fig. 2 outlines the different
apoptotic pathways PDA cell lines can undergo once infected and
important proteins that regulate them.
In agreement with our previous studies (Moerdyk-Schauwecker
et al., 2013; Murphy et al., 2012), most cell lines supported good VSV
replication (Fig. 3A), with the exception of Hs766T and HPAF-II which
are resistant to VSV even at high MOI infection. Also, in agreement
with our previous study (Moerdyk-Schauwecker et al., 2013), CFPAC-
1, HPAC, HPAF-II and Hs766T constitutively expressed MxA, while
VSV-induced expression of this ISG was observed in most other
PDACs. Although basal levels of another ISG, PKR, did not differ in
most cell lines [as previously shown (Moerdyk-Schauwecker et al.,
2013)], PKR protein levels were increased following VSV infection in
most cell lines with VSV-inducible type I IFN signaling.
In most PDAC cell lines, all 3 VSV recombinants induced caspase
3 cleavage following infection (Fig. 3B; cleaved products appear as a
double band at p17/p19). However, all 3 viruses induced similar (and
the highest) levels of caspase 3 cleavage only in Capan1 andMIA PaCa-
2. Both cell lines are unable to induce type I IFN responses to VSV
(Moerdyk-Schauwecker et al., 2013; Murphy et al., 2012). In all cell
lines with VSV-inducible type I IFN responses, despite similar replica-
tion levels for the 3 tested VSVs, VSV-ΔM51-GFP induced more
caspase 3 cleavage. This indicates a positive role for the ΔM51
mutation, and therefore host responses, in apoptosis induction, and
is unlikely to be simply a result of virus attenuation as VSV-p1-GFP
induced caspase cleavage similarly to VSV-GFP. In agreement with
their general resistance to VSV infection and replication (Moerdyk-
Schauwecker et al., 2013; Murphy et al., 2012), Hs766T and HPAF-II
showed the lowest levels of VSV protein accumulation in infected cells
VSV-GFP
3’
wt 
5’G LN P M GFP
VSV-p1-GFP
3’
wt 
5’G LN P MGFP
VSV-∆M51-GFP
3’
∆M51
5’G LN P M* GFP
Fig.1. Viruses used in this study. The viruses used in this study were VSV-ΔM51-
GFP, VSV-p1-GFP and VSV-GFP. VSV-ΔM51-GFP has a deletion of methionine at
amino acid position 51 of the M protein and the green ﬂuorescent protein (GFP)
ORF inserted at position 5 of the viral genome. VSV-GFP is similar to VSV-ΔM51-
GFP, but has wt M. VSV-p1-GFP also has wt M but GFP is inserted in position 1.
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(Fig. 3A). However, while Hs766T had no detectable cleaved caspase 3,
HPAF-II showed low but easily detectable caspase 3 cleavage in cells
infected with VSV-ΔM51-GFP and VSV-GFP (Fig. 3B.). Surprisingly,
HPAC cells, while supporting good levels of replication for all 3 tested
VSVs, had no detectable cleaved caspase 3. This result shows that VSV
replication is likely an important determinant of apoptosis, but it is not
sufﬁcient for apoptosis induction in PDAC cells.
The ability of VSV recombinants to induce apoptosis in PDAC cells
was also analyzed by measuring the activity of effector caspases
3 and 7 (Fig. 4). Hs766T and HPAC, which showed no detectable
cleaved caspase 3 (Fig. 3B), also showed the lowest caspase 3/7
activity (Fig. 4), again indicating a possible block(s) in apoptosis
upstream of caspase 3/7. Also consistent with Fig. 3B, only 2 PDAC
cell lines (Capan-1 and MIA PaCa-2) showed similar caspase 3/7
activity when infected with any of the three VSV recombinants,
while all other cell lines showed greater induction of apoptosis by
VSV-ΔM51-GFP (Fig. 4).
Apoptosis activation mechanism depends on both VSV M protein and
PDAC cell line
Previous studies in other cell types demonstrated that VSV M51
mutants typically activate apoptosis via the caspase 8 dependent
extrinsic pathway (Cary et al., 2011; Gaddy and Lyles 2005, 2007),
with the Fas receptor appearing to play a key role (Gaddy and Lyles
2007). The extrinsic apoptotic pathway can be either type I, where
caspase-8 cleavage is sufﬁcient to activate effector caspases, or
type II where the signal must be ampliﬁed through the intrinsic
pathway via caspase-8 cleavage of Bid (Barnhart et al., 2003;
Scafﬁdi et al., 1998). In contrast to VSV M51 mutants, VSV encoding
wt M protein typically activates apoptosis through the caspase
9 dependent intrinsic (mitochondrial) pathway (Balachandran et
al., 2001, 2000; Gaddy and Lyles 2005). VSV wt M protein likely
plays an important role in apoptosis induction by inhibiting host
gene expression (Kopecky and Lyles, 2003; Kopecky et al., 2001).
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Fig. 2. Pathways and proteins studied. Relationship between the apoptotic pathways. All proteins of interest for this study are in red.
Table 1
Relationship between apoptosis induction and IFN status of PDA cells.
Human cell
line
Origin VSV-induced
caspase
3 cleavage
VSV-induced
caspase
8 cleavagea
VSV-induced
caspase
9 cleavage
bVSV-
induced IFN-
β mRNA
bVSV-induced or
constit. IFN-α
mRNA
bConstit.
MxA and
OAS
bResist to VSV-
ΔM51 at low
MOI
bResist to VSV-
ΔM51 at high
MOI
M51 P1 WT M51 P1 WT M51 P1 WT
Capan-1 liver
metastasis
þþ þþ þþ þþ þþ þþ þþ þþ þþ N N N N N
MIA PaCa-2 primary
PDA
þþ þþ þþ þþ þþ þþ þþ þþ þþ N N N N N
Capan-2 primary
PDA
þþ þ þ þþ þ þ þþ þþ þþ Y Y N N N
AsPC-1 ascites þþ  þ þþ   þþ þ þþ Y Y N N N
Suit2 liver
metastasis
þþ   þþ   þþ   Y Y N N N
T3M4 lymph node
metastasis
þþ þ þ þ þ þ þþ þþ þþ Y Y N N N
CFPAC-1 primary
PDA
þþ  þ þþ  þþ þþ þ þþ Y Y Y Y N
HPAC primary
PDA
         Y Y Y Y N
HPAF-II primary
PDA
þ  þ    þ  þ Y Y Y Y Y
Hs766T lymph node
metastasis
         Y Y Y Y Y
“M51” – VSV-ΔM51-GFP; “P1” – VSV-p1-GFP; “WT” – VSV-GFP; “Y” – yes; “N” – no.
: low/not detectable levels.
þ: intermediate levels.
þþ: high levels.
a þþ Cleaved Caspase 8 p43/41 and p18 are detected,þ Cleaved Caspase 8 p 43/41 only is detected.
b Summarized from our previous studies (Moerdyk-Schauwecker et al., 2013; Murphy et al., 2012).
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Fig. 3. Protein levels of apoptosis related genes in PDAC cells following VSV infection. Cells were mock-infected or infected with VSV-ΔM51-GFP, VSV-p1-GFP or VSV-GFP at
an MOI of 15 (based on BHK-21 titer). At 17 h p.i, cell lysates were prepared and analyzed by Western blot for the indicated proteins associated with (A) virus replication and
antiviral response, (B) caspase cleavage, (C) the extrinsic apoptosis pathway, (D) the intrinsic apoptosis pathway and (E) total protein staining. Protein (kDa) product sizes are
indicated on the right. Due to a limited amount of total protein isolated from T3M4 and HPAC cells, the following exceptions were made: for PKR T3M4 sample, no protein
was loaded for uninfected T3M4 cells; for caspase 3 and FADD in HPAC cells 15 μg (half the amount) was loaded.
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However, the speciﬁc mechanism of apoptosis in response to VSV
infection depends on both virus and cell type (Balachandran et al.,
2001, 2000; Cary et al., 2011; Gaddy and Lyles 2005), and the
mechanism of apoptosis induction by VSV has never been studied
in PDAC cells.
As seen in Fig. 3B for VSV-ΔM51-GFP infected cells, where
cleavage of caspase 3 took place, cleavage of both caspase 8 and
9 was also detectable in all PDACs cell lines, except for HPAF-II,
indicating that this virus induces both the extrinsic and
intrinsic apoptosis pathways in most PDACs. Interestingly, in
HPAF-II cells, VSV-ΔM51-GFP induced caspase 9 but not cas-
pase 8 cleavage, suggesting that only the intrinsic pathway was
induced.
For VSV-GFP and VSV-p1-GFP, a predominance of caspase
9 cleavage to caspase 8 cleavage was seen in Capan-2, AsPC-1
and HPAF-II compared to other PDACs, suggesting induction of
apoptosis primarily through the intrinsic pathway as previously
reported for wt M. However, in all other cell lines cleavage of both
caspase 8 and caspase 9 was seen even upon infection with VSV
expressing wt M (Fig. 3B).
Having demonstrated heterogeneity in the ability of PDAC cell
lines to undergo apoptosis depending on both virus and cell, we
examined whether expression of major apoptosis regulator(s) could
account for these differences. Signaling through the Fas death
receptor has been shown to be required for VSV-M51R induced
apoptosis (Gaddy and Lyles 2007). Interestingly, two PDAC cell lines,
Hs766T and HPAF-II, most resistant to VSV replication and display-
ing no or low apoptosis induction in response to VSV, both showed
low levels of Fas receptor (Fig. 3C) compared to most other PDAC
cell lines, suggesting that low Fas levels could play a role in
resistance of these cell lines to VSV-mediated apoptosis. However,
two other PDAC cell lines (Capan-1 and Capan-2), also showed low
levels of Fas expression despite the lack of resistance to VSV
mediated apoptosis. Another apoptosis-resistant PDAC cell line,
HPAC, showed good levels of Fas receptor. FADD and Daxx have
both been shown to play important roles in Fas signaling
(Balachandran et al., 2000; Gaddy and Lyles 2007); however there
were no major differences between PDAC cell lines.
Bcl-2 family members have been shown to be altered in PDACs, as
well as other cancers, and to have predictive value for prognosis and
treatment response to chemotherapy and radiotherapy [reviewed in
Frenzel et al. (2009) and Westphal and Kalthoff (2003)]. This family is
part of the intrinsic pathway (and thus also the type II extrinsic
pathway) and contains both pro- and anti-apoptotic members. As
shown in Fig. 3D, Mcl-1, an anti-apoptotic protein, was consistently
expressed in all uninfected cell lines. However, Mcl-1 levels decreased
in most VSV-sensitive cell lines in response to infection with one or
more VSV recombinants, likely as part of the apoptosis initiation
process (Schache et al., 2009). Production of Bcl-2, an anti-apoptotic
protein, was highly variable and undetectable in a number of cell
lines. Hs766T was the only apoptosis-resistant PDAC cell line where
Bcl-2 was detectable, possibly explaining why it is more resistant to
VSV mediated apoptosis than other cell lines. However, Capan-1 and
MIA PaCa-2 cells, which efﬁciently activate apoptosis in response to
VSV infection, expressed Bcl-2 at equal or greater levels to Hs766T.
The anti-apoptotic protein Bcl-xL was expressed evenly among all cell
lines, indicating that this protein is probably not a key player in
resistance to VSV induced apoptosis, as were the pro-apoptotic
proteins Bak, Bax and Bid. Apoptosis-sensitive PDAC cell lines showed
Bid cleavage when infected with VSV-ΔM51-GFP. While a potential
biomarker of apoptosis resistance was not identiﬁed, it is known that
the ratio rather than the absolute quantity of these pro- and anti-
apoptotic proteins is important in the regulation of cell death
[reviewed in Wong (2011)]. Further studies are needed to determine
a role of these apoptotic regulators in the resistance of some PDACs to
VSV induced apoptosis.
VSV-ΔM51 induces apoptosis in PDACs via the type II extrinsic
pathway
The major focus of this study was VSV-ΔM51-GFP. Therefore,
the mechanism of apoptosis induction during VSV-ΔM51-GFP
infection was studied in more detail. As shown in Fig. 3B, where
cleavage of caspase 3 took place, cleavage of both caspase 8 and
9 was also detectable in all VSV-ΔM51-GFP infected cells (except
for HPAF-II). Cleavage of both caspases 8 and 9 can result from
either activation of the type II extrinsic pathway (where caspase
8 is essential for the activation of caspases 9 and 3), independent
activation of intrinsic and extrinsic pathways, or death receptor-
independent activation of caspase 8 as part of a positive feedback
loop following cleavage of caspase 3 after initial activation of the
intrinsic pathway (Liu et al., 2011). As VSV with M51 mutations
frequently induces apoptosis via the extrinsic pathway (Gaddy and
Lyles 2005, 2007) and pancreatic cells have been shown to utilize
the type II extrinsic pathway (Hinz et al., 2000), we hypothesized
that VSV-ΔM51-GFP induced apoptosis in PDAC cells via this
mechanism.
To test this hypothesis, infections with VSV-ΔM51-GFP at MOI
15 (based on BHK-21 titer) were conducted in the presence of
Z-VAD-FMK, a pan-caspase inhibitor, or Z-IETD-FMK, a caspase
8 speciﬁc inhibitor. Following treatment, cleavage of caspase 3 was
measured by ELISA at 17 h p.i. As shown in Fig. 5, most PDAC cell
lines showed a strong increase in caspase 3 cleavage following
VSV-ΔM51-GFP infection in agreement with the Western blot
analysis (Fig. 3B) and the caspase activity assay (Fig. 4). The two
PDAC cell lines (HPAC and Hs766T), which showed minimal
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Fig. 4. Caspase 3/7 activation in PDAC cells following VSV infection. Cells were mock- or virus-infected at an MOI of 15 (based on BHK-21 titer). At 24 h p.i., apoptosis
activation was assessed using the Caspase Glow 3/7 assay. Caspase 3/7 activation is expressed as fold increase over mock treated, with the mock treated activity indicated as
1. Assay was done in triplicate and data represent the mean7standard error of mean. Treatments were compared using a 1-way ANOVA followed by the Bonferroni posttest
for comparison to the control. *, po0.05; **, po0.01; ***, po0.001.
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caspase 3 activity and cleavage in the previous assays again
showed low levels of cleaved caspase 3. Importantly, treatment
with Z-IETD-FMK returned cleaved caspase 3 levels to near base-
line in all cell lines, indicating caspase 8 is critical to apoptosis
induction following VSV-ΔM51-GFP infection. As caspase 9 clea-
vage was also seen in all these PDAC cell lines (Fig. 3B), we
concluded that apoptosis occurred through the type II extrinsic
pathway. This mechanism is also consistent with the detection of
cleaved Bid in many PDACs cell lines infected with VSV-ΔM51-GFP
(Fig. 3D).
Role of virus replication levels and type I interferon in apoptosis
induction in PDAC cell lines
Under the experimental conditions shown in Fig. 3 (MOI 15
infection), VSV replication was severely inhibited in HPAF-II and
Hs766T. No (Hs766T) or low (HPAF-II) caspase 3 cleavage (Fig. 3B)
could potentially be attributed to very low levels of virus replica-
tion in these 2 cell lines. However, HPAC cells, while supporting
good levels of VSV replication, showed no detectable cleaved
caspase 3, indicating that good VSV replication levels are not
sufﬁcient for apoptosis induction at least in some PDAC cells. All
three cell lines (HPAC, HPAF-II and Hs766T) as well as CFPAC-1
constitutively express some ISGs, including MxA [Fig. 6 and
(Moerdyk-Schauwecker et al., 2013)]. Therefore, we conducted
an experiment to test the hypothesis that resistance of PDAC cells
to VSV-mediated apoptosis is the result of upregulated type I IFN
signaling leading to low-level VSV replication and/or expression of
one or more anti-apoptotic factors. As controls, we used MIA PaCa-
2 cells, which are defective in type I IFN signaling, as well as
CFPAC-1 cells, which are similar to HPAC cells in their constitutive
expression of ISGs, but, unlike HPAC, undergo apoptosis following
VSV infection.
Inhibition of type I IFN signaling and subsequent increase in VSV-
ΔM51-GFP replication levels were achieved by treatment of cells with
Jak Inh. I as in our previous study (Moerdyk-Schauwecker et al., 2013).
Cells lines were mock-infected or infected at MOI 15 (based on BHK-21
titer) with VSV-ΔM51-GFP and protein was isolated at 17 h p.i.. MxA
protein was downregulated in all treated cell lines, conﬁrming Jak Inh.
I treatment was effective. Importantly, although Jak Inh. I treatment
increased VSV-ΔM51-GFP replication in PDAC cell lines with
constitutive ISG expression, it did not result in increased caspase
3 cleavage (Fig. 6). These results demonstrate that even when viral
replication is increased and type I IFN signaling inhibited, HPAC and
Hs766T cannot efﬁciently activate apoptosis. Therefore, there is no
clear correlation between VSV-ΔM51-GFP replication levels or type I
IFN signaling and apoptosis in these two cell lines. To not miss effects
of Jak Inh. I treatment upstream of caspase 3, we looked also for
changes in cleavage of caspases 8 and 9 and expression of extrinsic/
intrinsic regulators and did not see any major changes (Fig. 6).
Activation of apoptosis by non-viral stimulators
Since VSV-ΔM51-GFP was unable to effectively induce apoptosis
in Hs766T and HPAC and weakly and variably induced apoptosis in
HPAF-II, we wanted to know whether these cell lines resist only
virus mediated apoptosis or if they have a more general defect in
apoptosis. Therefore, we tested if the extrinsic apoptosis pathway
could be induced using a virus independent method. Hs766T, HPAC,
HPAF-II and MIA PaCa-2 were treated with Fas activating antibody
CH11, TNF-α, TNF-related apoptosis-inducing ligand (TRAIL) or
VSV-ΔM51-GFP and tested for caspase-3 cleavage at 17 h p.i. All
stimulators induced caspase 3 cleavage in MIA PaCa-2 but
VSV-ΔM51-GFP appeared to do so most effectively (Fig. 7). TNF-α
did not induce apoptosis in any of the PDAC cell lines resistant to
VSV mediated apoptosis. Fas activating antibody CH11 more strongly
induced caspase 3 cleavage in HPAC than in Hs766T and HPAF-II,
consistent with Fas receptor levels (Figs. 3C and 6). Finally, consis-
tent with previous data, VSV-ΔM51-GFP did not induce caspase
3 cleavage in HPAC, Hs766T and HPAF-II cells. Together, the data
suggest that at least two of the three PDAC cell lines resistant to
VSV mediated apoptosis have a more general defect in apoptosis.
Impact of apoptosis on VSV-ΔM51-GFP replication
While strong inhibition of apoptosis in response to VSV-ΔM51-
GFP infection can prevent oncolysis, rapid induction of apoptosis can
potentially have an antiviral effect by destroying the infected cell
before the virus reaches its maximum replication potential. As this
could limit the effectiveness of VSV as an oncolytic virus, we
examined the possible effects of apoptosis induction on VSV-ΔM51-
GFP replication in PDAC cells. Two cell lines (VSV-permissive MIA
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Fig. 5. Effect of caspase inhibitors on caspase 3 cleavage. Cells were pretreated with 100 mM caspase-8 inhibitor Z-IETD-FMK, 100 mM general caspase inhibitor Z-VAD-FMK
or vehicle only (DMSO) in growth media for 1 h prior to infection. Cells were then mock infected or infected with VSV-ΔM51-GFP at an MOI of 15 PFU/cell (based on BHK-21
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PaCa-2 and VSV-resistant HPAF-II) were infected with VSV-ΔM51-GFP
in the presence or absence of Z-VAD-FMK (a pan-caspase inhibitor) or
Z-IETD-FMK (a caspase 8 speciﬁc inhibitor). Cells were infected at a
cell line speciﬁc MOI of 2 to ensure one-step growth kinetics, and
virus replication was monitored by measuring virus-directed GFP
ﬂuorescence in live cells (Fig. 8A) and measuring new particle
production by titration of media on BHK-21 cells (Fig. 8B). GFP
expression only modestly (although statistically signiﬁcant at most
time points) increased in inhibitor-treated cells (Fig. 8A). However, no
statistically signiﬁcant increase in new particle production was seen
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in MIA PaCa-2 cells at any time point, and an increase was only seen
in HPAF-II at 120 h p.i. (Fig. 8B). The tolerance of VSV replication to
apoptosis in MIA PaCa-2 and HPAF-II is most likely due to VSV's
relatively fast replication cycle, allowing it to outpace the apoptotic
response (Koyama, 1995; Timm and Yin, 2012).
Discussion
In this study, we investigated apoptosis activation in human PDAC
cells in response to three different VSV recombinants expressing
ΔM51 or wild type M protein. We demonstrated that VSV-ΔM51 is a
more potent inducer of apoptosis in the majority of PDAC cells than
VSV with wt M, and that it activates apoptosis mainly via the type II
extrinsic pathway. We also showed that resistance of some PDAC cell
lines to VSV-mediated oncolysis is not due only to type I IFN
responses that limit virus replication (Moerdyk-Schauwecker et al.,
2013; Murphy et al., 2012), but also to cellular defects in apoptosis.
Our study investigated VSV-mediated apoptosis in pancreatic
cancer cells for the ﬁrst time. Previous studies in other systems
showed VSV-M51R mutation activated apoptosis mainly via the
caspase 8 dependent extrinsic pathway (Cary et al., 2011; Gaddy
and Lyles 2005, 2007), while VSV encoding wt M protein typically
activated apoptosis through the caspase 9 dependent intrinsic
pathway (Balachandran et al., 2001, 2000; Gaddy and Lyles 2005).
However, this distinction is not absolute as either or both path-
ways can be activated during infection with either variant
(Balachandran et al., 2001; Cary et al., 2011). Our data show a
similar situation in PDAC cells. Despite similar levels of replication
in most cell lines (except for Hs766T and HPAF-II which are highly
resistant to VSV), VSV-GFP virus induced both intrinsic and
extrinsic pathways in most PDAC cell lines, but only the intrinsic
pathway in Capan-2 and AsPC-1 cell lines. This suggests that
cellular factors can determine the mechanism of apoptosis
mediated by the same virus. However, viral factors can also
determine the mechanism of apoptosis. For example, compared
to VSV-GFP, VSV-ΔM51-GFP caused signiﬁcantly stronger apopto-
sis in Suit2, Capan-2, T3M4 and AsPC-1 cells, even though both
viruses replicated to similar levels in these 4 cell lines.
The role of type I IFN signaling and ISGs in apoptosis induction
in PDAC cells is not well understood. Consistent with the anti-
proliferative and pro-apoptotic effects generally associated with
type I IFN responses, treatment with exogenous type I IFN has
been shown to induce apoptosis in at least some PDAC cell lines,
although induction efﬁciency varied considerably across cell lines
(Booy et al., 2014). Many ISGs, including Fas ligand, TRAIL and
several IRFs, have known pro-apoptotic effects [reviewed in
Chawla-Sarkar et al. (2003) and Cheon et al. (2014)]. Some
antiviral ISGs, including OAS-RNase L and PKR, have also been
shown to have pro-apoptotic roles [reviewed in Clemens (2003)].
However, other ISGs (for example, IFI6, also known as G1P3 or
ISG6-16) are known to be anti-apoptotic (Cheriyath et al., 2007;
Cheriyath et al., 2011).
The role of ISGs in VSV-mediated apoptosis is also complex. PKR
in particular has been shown to be important for efﬁcient induction
of apoptosis by VSV-M51R mutation in mouse ﬁbrosarcoma cells
(Gaddy and Lyles 2007). In contrast, PKR does not appear to be
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important for induction of apoptosis by VSV with wt M protein
(Balachandran et al., 2000). Moreover, cellular PKR expression was
associated with resistance to wt VSV infection, apoptosis induction
and killing (Balachandran et al., 2000). Together, these studies
suggest that ISG expression is beneﬁcial for apoptosis induction by
VSV-M51 mutants (due to PKR and other factors), but negatively
impacts apoptosis induction by VSV expressing wt M due to
inhibitory effects on viral replication.
Our results are consistent with induction/enhancement of apopto-
sis by ISGs in PDAC cell lines permissive to VSV and showing VSV
inducible type I IFN signaling (Fig. 3 and Table 1) (Moerdyk-
Schauwecker et al., 2013). In these cell lines, VSV-ΔM51-GFP was a
more effective apoptosis inducer than VSV recombinants expressing
wt M. Unlike wt M protein, M proteinwith an M51 mutation is unable
to block type I IFNmediated antiviral responses in infected cells (Stojdl
et al., 2003) and allows for expression of ISGs, including pro-apoptotic
ISGs, in response to infection.
In contrast to PDACs with VSV inducible ISG expression, it is
likely that constitutive high-level expression of ISGs in VSV-
resistant PDAC cell lines negatively impacts VSV-mediated apop-
tosis by dramatically inhibiting virus replication (regardless of M
protein variant). Furthermore, the pattern of ISG expression differs
in response to acute virus infection or IFN treatment as compared
to chronic virus infection (Li et al., 2014; Wilson et al., 2013) or
diseases involving chronic type I IFN production, including some
cancers (Cheon et al., 2014). Thus, the role of ISGs in apoptosis
induction in response to VSV infection may be different in cancers
with constitutive versus inducible expression of ISGs.
Importantly, our data also show that type I IFN responses are not
required for robust VSV induced apoptosis in PDAC cells. Two PDAC cell
lines defective in type I IFN signaling in response to VSV, MIA PaCa-2
and Capan-1, supported the highest levels of caspase cleavage in
response to VSV infection regardless of M protein status. In this
instance, the absence of the pro-apoptotic effect of type I IFN responses
is likely compensated for by the uninhibited replication of virus.
Overall, VSV-ΔM51-GFP is a potent inducer of apoptosis in the
majority of PDAC cell lines. This is signiﬁcant, as PDACs are known to
be highly resistant to a variety of chemotherapies in part because of
defects in apoptosis (Hamacher et al., 2008; Neesse et al., 2012; Roder
et al., 2011). This result not only speaks to the potential of VSV-ΔM51-
GFP as an oncolytic agent but also suggests it may also be useful as a
sensitizer to chemotherapy. In several cancers, VSV-M51R infection
improved doxorubicin treatment by facilitating degradation of the
anti-apoptotic protein Mcl-1 (Schache et al., 2009), while another
study showed that wt VSV in combinationwith gemcitabine increased
apoptosis and increased killing of lung cancer cell lines in vitro and
in vivo (Li et al., 2004). If successful, such combination therapies could
allow for equal or greater efﬁcacy at lower doses of chemotherapeutic
drug, reducing side effects in patients.
Furthermore, while VSV-ΔM51-GFP was a potent inducer of
apoptosis in most PDAC cells, apoptosis had little or no antiviral effect
on VSV-ΔM51-GFP replication in PDAC cells. This was also previously
demonstrated for VSV in several other systems (Balachandran et al.,
2001; Hobbs et al., 2003, 2001; Sharif-Askari et al., 2007) and is most
likely due to VSV's relatively fast replication cycle in most cells,
allowing the virus to complete its replication cycle prior to cell death.
Interestingly, other studies have shown that inhibition of apoptosis can
increase VSV replication (Chattopadhyay et al., 2011; Desforges et al.,
2002; Sharif-Askari et al., 2007), indicating that small variations in
viral replication or apoptosis kinetics likely determine whether or not
an apoptotic response negatively impacts VSV replication. Given this,
while cancer related apoptosis defects can be a therapeutic barrier,
they may actually beneﬁt VSV oncolytic therapy in many cases by
allowing VSV to “win” the race against this antiviral mechanism.
Apoptosis defects may also be another mechanism increasing VSV
speciﬁcity for cancerous versus normal tissue as has been shown for
other oncolytic viruses (Liu and Kirn, 2005). In general, induction of
apoptosis does not seriously impact VSVs ability to replicate in cancer
cells, making it a promising oncolytic virus and suggesting that
cotherapy with agents that induce and/or enhance apoptosis should
be feasible.
While VSV-ΔM51-GFP was a potent inducer of apoptosis and
subsequent cell death in most PDAC cells, this was not the case in
some PDAC cell lines. Three PDAC cell lines, Hs766T, HPAC and
HPAF-II, with the strongest resistance to VSV-ΔM51-GFP mediated
apoptosis were known from our previous studies to have consti-
tutive expression of some antiviral IFN-stimulated genes
(Moerdyk-Schauwecker et al., 2013; Murphy et al., 2012). At least
in case of HPAC cells, failure to undergo apoptosis was not due to
low VSV replication levels. The inability of Hs766T and HPAF-II
cells to undergo apoptosis could be due to limited VSV-ΔM51-GFP
replication. However, increasing viral replication via inhibition of
constitutive type I IFN responses did not improve induction of
apoptosis. It should be noted that we cannot rule out that
stimulation of VSV replication using Jak Inh. I was counteracted
by simultaneous inhibition of the potentially pro-apoptotic effects
of type I IFN signaling. In particular, this case is distinct from that
of MIA PaCa-2 and Capan-1, as while Jak Inh. I facilitates virus
replication and spread, initiation of infection in resistant cell lines
remains relatively inefﬁcient (Moerdyk-Schauwecker et al., 2013).
In addition to resisting apoptosis induction by VSV, Hs766T and
HPAF-II were also resistant to apoptosis when treated with Fas
activating antibody. Therefore, our data indicate two separate
mechanisms behind resistance of PDAC cells to VSV-ΔM51-GFP
mediated apoptosis: (1) virus-speciﬁc defects in apoptosis, as seen
with HPAC, where Fas activating antibody can induce apoptosis
but virus-induced apoptosis is signiﬁcantly inhibited, or (2) general
defects in Fas receptor mediated apoptosis, as seen with the
Hs766T and HPAF-II cells, where apoptosis cannot be induced
effectively by virus or Fas activating antibody.
As PDAC cell lines that evaded VSV-ΔM51-GFP mediated apop-
tosis activation showed no or low levels of cleaved caspase 8 and 9,
it is likely that cellular factors upstream of these initiator caspases
are involved in this resistance (Hanahan and Weinberg, 2011; Kelly
and Strasser, 2011). As TRAIL was relatively effective in inducing
apoptosis in all these cell lines, the defect(s) may primarily impact
the Fas receptor mediated pathway. Fas receptor was expressed at
lower levels in Hs766T cells than in many other cell lines, which
may contribute to its apoptosis resistance. Evasion of apoptosis by
PDACs is commonly impacted by overexpression of Fas decoy
receptors (DcR3), Fas associated phosphatase-1 (FAP-1), and/or
FLICE-inhibitory protein c-FLIP (Hamacher et al., 2008; Neesse et
al., 2012; Roder et al., 2011), all of which target events upstream of
caspase 8. Our future studies will examine these factors.
Although we did not ﬁnd a relationship between expression of Bcl-
2 proteins and resistance of PDAC cell lines to VSV-ΔM51-mediated
oncolysis, further studies are also needed to determine the inﬂuence
of these or other regulators downstream of caspase 8 and 9 such as
inhibitors of apoptosis (IAPs) (Hamacher et al., 2008). Our future
studies will also examine the role of other types of cell death in VSV
infected PDACs, particularly autophagy as VSV has already been
reported to induce autophagy in different types of cancer cells
(Schache et al., 2009).
Materials and methods
Viruses
VSV-ΔM51-GFP and VSV-p1-GFP viruses were kindly provided
by Jack Rose (Yale University), and VSV-GFP virus was kindly
provided by Asit Pattnaik (University of Nebraska). All 3 VSV
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recombinants are based on the same full-length VSV (Indiana
serotype) cDNA clone (Lawson et al., 1995), which contains the L
gene and the N-terminal 49 residues of the N gene from the
Mudd-Summers strain, and the remainder of the genome from the
San Juan strain (both belonging to the Indiana serotype). VSV-
ΔM51-GFP has a deletion of methionine at amino acid position 51
of the M protein and the green ﬂuorescent protein (GFP) ORF
inserted at position 5 of the viral genome (Wollmann et al., 2010).
VSV-GFP is similar to VSV-ΔM51-GFP, but has wt M (Das et al.,
2006). VSV-p1-GFP also has wt M but GFP is inserted in position 1
(Wollmann et al., 2010). Viruses were grown in BHK-21. Viral titers
were determined by standard plaque assay on BHK-21 cells and
expressed as plaque forming units (PFU) per ml.
Cell lines
The human PDAC cell lines used in this study were kindly
provided by the following individuals in Fall 2010: David McCon-
key (M. D. Anderson Cancer Center): CFPAC-1 and Hs766T cells;
Randall Kimple (UNC-Chapel Hill): Capan-2 and T3M4 cells;
Timothy Wang (Columbia University): AsPC-1 cells; Andrei Ivanov
(University of Rochester Medical School): HPAF-II cells; Michael
Hollingsworth (University of Nebraska Medical Center): Suit2
cells; Emmanuel Zervos (Tampa General Hospital): HPAC cells;
Pinku Mukherjee (University of North Carolina at Charlotte):
Capan-1, MIA PaCa-2 and Panc-1 cells. Cells were maintained as
previously described (Moerdyk-Schauwecker et al., 2013). After
receipt, the human origin of all cell lines was conﬁrmed by partial
sequencing of KRAS and actin. As expected, all PDAC cell lines had
a mutation in KRAS, as is typical for PDACs (data not shown).
Drugs
The following drugs were used in this study: recombinant
career-free (CF) human TNF-α (R&D Systems); recombinant human
TNF-related apoptosis-inducing ligand (TRAIL) (Millipore); Fas
activating antibody (Millipore, clone CH11); caspase-8 inhibitor
Z-IETD-FMK (R&D Systems); pan-caspase inhibitor Z-VAD-FMK
(R&D Systems) and Jak Inh. I (“InSolution”, Calbiochem).
Western blot
Cellular lysates and Western blots were prepared as previously
described (Moerdyk-Schauwecker et al., 2013). Cell lysates were
collected at 17 h p.i. following infection at MOI 15 (based on BHK-
21 titer). Due to a limited amount of total protein isolated from T3M4
and HPAC cells, the following exceptions were made: for PKR T3M4
sample, no protein was loaded for uninfected T3M4 cells; for caspase
3 and FADD in HPAC cells 15 μg (half the amount) was loaded. The
following primary antibodies were used in TBS-T with 5% BSA or milk
and 0.02% sodium azide: 1:10,000 rabbit polyclonal anti-VSV anti-
bodies (raised against VSV virion proteins), 1:1000 anti-MxA (clone
631–645) antibodies from Sigma, and the following antibodies from
Cell Signaling Technology (1:1000 or 1:500): caspase 3, caspase 8
(clone 1C12), caspase 9, Bak, Bax (clone D2E11), BID, Bcl-2 (clone
50E3), Bcl-xL (clone 54H6), Daxx (clone 25C12), FADD, Fas (clone
4C3), Mcl-1 (clone D35A5). The following horseradish peroxidase-
conjugated secondary antibodies were used: 1:2000 goat anti-mouse
and 1:2000 goat anti-rabbit (Jackson-ImmunoResearch). The Amer-
sham ECL Western Blotting Detection Kit (GE Healthcare) or Pierce
SuperSignal West Pico Detection Kit (Thermo Scientiﬁc) was used for
detection. Membranes were Coomassie blue stained to verify sample
loading. When Jak Inh. I treatment was used, 6-well plates were
seeded such that they were approximately 80% conﬂuent at the time
of inhibitor treatment. Cells were treated with 2.5 μM Jak Inh. I or
vehicle (DMSO) only in cell culture media with 5% FBS for 48 h prior
to infection (media was removed and replaced with fresh drug/
vehicle containing media after the ﬁrst 24 h). Cells were then mock
infected or infected with VSV-ΔM51-GFP in DMEM without FBS at an
MOI of 15 (based on BHK-21 titer). Following a 1 h absorption period,
the virus containing media was aspirated and replaced with growth
media with 5% FBS containing either 2.5 μM Jak Inh. I or vehicle. At
17 h p.i., cells were collected and used to prepare cellular lysates for
Western blotting as described above.
Cell based apoptosis detection
For detection of apoptosis induction following virus infection,
cells were seeded in 96-well plates such that they were approxi-
mately 80% conﬂuent at the time of treatment. Cells were then mock-
or virus-infected at an MOI of 15 (based on BHK-21 titer). Following a
1 h absorption period, the virus containing media was aspirated and
replaced with growth media containing 5% FBS. At 24 h p.i., apoptosis
activation was assessed using the Caspase Glow 3/7 assay (Promega)
in accordance with manufacturer instructions. When inhibitors of
apoptosis were used, cells were pretreated with 100 mM caspase-8
inhibitor Z-IETD-FMK, 100 mM pan-caspase inhibitor Z-VAD-FMK or
vehicle only (DMSO diluted in PBS) in growth media for 1 h prior to
infection. Cells were then mock infected or infected with VSV-ΔM51-
GFP at an MOI of 15 (based on BHK-21 titer), or treated with 1 μg/ml
Fas activating antibody, 1 μg/ml TRAIL, or 25 ng/ml TNF-α in the
continued presence of either inhibitor or vehicle. Following a 1 h
absorption period, the virus containing media was aspirated and
replaced with growth media with 5% FBS (experiments using only
virus) or no FBS (experiments also utilizing other drugs) containing
either inhibitor or vehicle. At 17 h p.i., apoptosis activation was
assessed using the Cleaved Caspase-3 In-Cell ELISA (Thermo Scien-
tiﬁc), in accordance with manufacturer instructions. Alternatively,
cells were infected at a cell line speciﬁc MOI of 2 to ensure one-step
growth kinetics, and then treated with inhibitors of apoptosis as
above. At the indicated time points, virus replication was monitored
by measuring virus-directed GFP ﬂuorescence in live cells [CytoFluor
Series 4000 (Perseptive Biosystems), with excitation ﬁlter of 485/
20 nm, emission ﬁlter of 530/25 nm and gain¼50] and by collecting
virus containing media for titration on BHK-21 cells.
Statistical analysis
All statistical analyses were performed using GraphPad Prism,
version 5.03 for Windows (GraphPad Software, San Diego, Cali-
fornia). Caspase 3/7 activity and caspase 3 cleavage within a cell
line were analyzed by one-way ANOVA with Bonferroni post-test
for comparison to the control. Virus driven GFP expression and
virus replication following caspase inhibitor treatment was ana-
lyzed by repeated measures two-way ANOVA with Bonferroni
post-test, following log transformation of replication values to
increase normality.
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